Brief: Vaxcyte Appoints Chief Medical Officer And Chief Legal Officer Narrows Guidance For Expected Vax-31 Opus-1 Topline Data
Vaxcyte, Inc. reports results for the quarter ended June 30 - Earnings Summary
Vaxcyte Q2 net loss widens on higher expenses
Brief: Vaxcyte Q2 Operating Expenses USD 302.777 Million
Brief: Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults
Vaxcyte Q1 net loss widensas costs rise
Brief: Vaxcyte Q1 Operating Expenses USD 345.85 Million
Brief: Vaxcyte Completes Enrollment Of Opus-1 And Opus-2 Phase 3 Trials Evaluating Vax-31 For The Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults
Brief: Vaxcyte Publishes Positive Vax-31 Phase 1/2 Adult Study Results In The Lancet Infectious Diseases
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP
Brief: Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million
U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
U.S. STOCKS ON THE MOVE-Charter Communications, Western Digital, Regeneron
Vaxcyte edges higher after upsized $550 mln equity raise
Vaxcyte dips after commencing $500 mln stock offering
Brief: Vaxcyte Advances Adult And Infant Programs For Vax-31, A Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine
Brief: Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
U.S. RESEARCH ROUNDUP- Equifax, Johnson & Johnson, Morgan Stanley